Key result
RAAS inhibitor therapy is linked to fewer hemocompatibility-related adverse events during LVAD support.
Why the study?
Does the use of a RAAS inhibitor reduce hemocompatibility-related adverse events in patients receiving LVAD therapy?
RCT
Does the use of a RAAS inhibitor reduce hemocompatibility-related adverse events in patients receiving LVAD therapy?
The use of RAAS inhibitors may enhance hemocompatibility and reduce adverse events in patients with HeartMate 3 LVADs.
Background pharmacologic therapy did not modify the effect of aspirin on HRAE; however, the use of a RAAS inhibitor was independently associated with a reduction in HRAE. These exploratory observations may potentially point to opportunity for enhancing hemocompatibility in patients receiving LVAD therapy. (Antiplatelet Removal and Hemocompatibility Events With the HeartMate 3 Pump [ARIES-HM3]; NCT04069156).
No takes yet. Share an insight, caveat, or question.
Katz et al. (2025) conducted an RCT in LVAD therapy. RAAS inhibitor was evaluated on Hemocompatibility-related adverse events (HRAE). The use of a RAAS inhibitor was independently associated with a reduction in hemocompatibility-related adverse events in patients receiving LVAD therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: